Edition:
United States

Pharming Group NV (PHGUF.PK)

PHGUF.PK on OTC Markets Group - US Other OTC and Grey Market

0.25USD
23 Sep 2016
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.25
Open
$0.25
Day's High
$0.25
Day's Low
$0.25
Volume
2,000
Avg. Vol
20,290
52-wk High
$0.35
52-wk Low
$0.17

PHGUF.PK

Chart for PHGUF.PK

About

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies. The Company’s products... (more)
No analyst recommendations are available for PHGUF.PK.

Overall

No Ratios Available.

Financials

  PHGUF.PK Industry Sector
P/E (TTM): -- 42.52 36.60
EPS (TTM): -- -- --
ROI: -- -0.26 13.91
ROE: -- -3.05 14.82

Valeant looks to sell billions in assets to cut debt, stock soars

Valeant Pharmaceuticals International Inc will sell billions of dollars of non-core assets and could accept offers for its main businesses, its chief executive said on Tuesday, as the drugmaker worked to restore investor trust after a year of bad news.

Aug 09 2016

UPDATE 6-Valeant looks to sell billions in assets to cut debt, stock soars

Aug 9 Valeant Pharmaceuticals International Inc will sell billions of dollars of non-core assets and could accept offers for its main businesses, its chief executive said on Tuesday, as the drugmaker worked to restore investor trust after a year of bad news.

Aug 09 2016

BRIEF-Pharming Group announces acquisition of all North American commercialisation rights to Ruconest from Valeant

* Announces acquisition of all North American commercialisation rights to Ruconest from Valeant

Aug 09 2016

BRIEF-Valeant Pharmaceuticals Q2 GAAP loss per share $0.88

Aug 9 Valeant Pharmaceuticals International Inc :

Aug 09 2016

BRIEF-Pharming Group H1 operating loss at 6.2 million euros

* H1 revenues 5.3 million euros ($5.86 million) versus 5.2 million euros year ago

Jul 28 2016

BRIEF-Pharming Group announces positive results from a phase 2 clinical study of RUCONEST

* Announced positive results from a phase 2 clinical study of RUCONEST

Jul 18 2016

BRIEF-Pharming Group amends Ruconest distribution agreement with Sobi

* Pharming to directly commercialise Ruconest in 21 additional Western European, North African and Middle-Eastern markets

Jul 14 2016

REFILE-BRIEF-Pharming Group Q1 net loss widens to 3.4 million euros

* Net loss increased from 1.3 million euros ($1.47 million) in Q1 2015 to 3.4 million euros in Q1 2016

May 18 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : Sadif Analytics Prime
$25.00
Provider : Sadif Analytics Prime
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.